

W/723,473

FILE 'HOME' ENTERED AT 18:05:45 ON 10 SEP 2006

=> file biosis medline caplus wpids uspatfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.63	0.63

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 18:07:25 ON 10 SEP 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 18:07:25 ON 10 SEP 2006

FILE 'CAPLUS' ENTERED AT 18:07:25 ON 10 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 18:07:25 ON 10 SEP 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 18:07:25 ON 10 SEP 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> s dithiobenzyl

L1 188 DITHIOBENZYL

=> s l5 and hydropholic (3a) polymer?

L5 NOT FOUND

The L-number entered could not be found. To see the definition  
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l1 and hydropholic (3a) polymer?

L2 0 L1 AND HYDROPHOLIC (3A) POLYMER?

=> s l1 and hydrophilic (3a) polymer?

L3 30 L1 AND HYDROPHILIC (3A) POLYMER?

=> s l3 and amine

L4 28 L3 AND AMINE

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 22 DUP REM L4 (6 DUPLICATES REMOVED)

=> s l5 and polypeptide

L6 10 L5 AND POLYPEPTIDE

=> d l6 bib abs 1-10

L6 ANSWER 1 OF 10 USPATFULL on STN

AN 2006:93355 USPATFULL

TI Lipopolymer conjugates

IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES

PI US 2006079486 A1 20060413

AI US 2005-245673 A1 20051007 (11)

PRAI US 2004-617585P 20041008 (60)

DT Utility

FS APPLICATION

LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 766

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugates of formula I, below, are useful in biomedical applications such as delivery of drugs or labeling moieties or as components of liposomes or micelles. In formula I, A is a hydrophilic polymer, each of L and L' is independently a linker group, B is a lipid moiety; and Z is a diagnostic ligand, a biologically relevant ligand, or a reactive linking moiety, which is generally linked to the phosphorus atom of the conjugate via a nitrogen, oxygen or sulfur atom in Z. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 10 USPATFULL on STN

AN 2006:68015 USPATFULL

TI Endogenously-formed conjugate of albumin

IN Hutchins, Maria U., Mountain View, CA, UNITED STATES

Kiwan, Radwan, Albany, CA, UNITED STATES

Zalipsky, Samuel, Redwood City, CA, UNITED STATES

PI US 2006058236 A1 20060316

AI US 2005-217536 A1 20050831 (11)

PRAI US 2004-607110P 20040903 (60)

DT Utility

FS APPLICATION

LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 28 Drawing Page(s)

LN.CNT 1244

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A conjugate formed in vivo and comprised of endogenous albumin and an amine-containing compound, such as a protein or a drug, is described. The conjugate is formed by in vivo cleavage of a polymer-dithiobenzyl-therapeutic agent conjugate to form an albumin-dithiobenzyl-therapeutic agent conjugate. The dithiol moiety of the albumin-therapeutic agent conjugate is cleaved in vivo to yield the free therapeutic agent in native form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 10 USPATFULL on STN

AN 2005:312098 USPATFULL

TI Conjugate having a cleavable linkage for use in a liposome

IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES

Gabizon, Alberto A., Jerusalem, ISRAEL

PI US 2005271715 A1 20051208

AI US 2005-202913 A1 20050812 (11)

RLI Continuation of Ser. No. US 2002-57831, filed on 23 Jan 2002, PENDING  
Continuation of Ser. No. US 2000-556610, filed on 21 Apr 2000, GRANTED,  
Pat. No. US 6365179

PRAI US 1999-130897P 19990423 (60)

DT Utility

FS APPLICATION

LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 1240

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its

original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 10 USPATFULL on STN  
AN 2005:305288 USPATFULL  
TI Releasable linkage and compositions containing same  
IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES  
Subramony, Paramjeet, Santa Clara, CA, UNITED STATES  
PI US 2005265925 A1 20051201  
AI US 2005-110272 A1 20050420 (11)  
PRAI US 2004-564565P 20040421 (60)  
DT Utility  
FS APPLICATION  
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 1134

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugates comprising a lipid or a hydrophilic polymer  
, such as polyethyleneglycol, linked to a ligand derived from an  
amine- or hydroxyl-containing compound, such as a drug or  
protein, are stable under conditions of storage, and are cleavable under  
mild thiolytic conditions to regenerate the amine- or  
hydroxyl-containing compound in its native form, without the formation  
of undesirable side products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 10 USPATFULL on STN  
AN 2005:143862 USPATFULL  
TI Releasable linkage and compositions containing same  
IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES  
PA Alza Corporation (U.S. corporation)  
PI US 2005123597 A1 20050609  
AI US 2005-35707 A1 20050114 (11)  
RLI Continuation of Ser. No. US 2003-371169, filed on 21 Feb 2003, GRANTED,  
Pat. No. US 6849270 Continuation of Ser. No. US 2001-982336, filed on 15  
Oct 2001, GRANTED, Pat. No. US 6605299 Continuation of Ser. No. US  
2000-556056, filed on 21 Apr 2000, GRANTED, Pat. No. US 6342244  
PRAI US 1999-130897P 19990423 (60)  
DT Utility  
FS APPLICATION  
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1-47  
DRWN 16 Drawing Page(s)  
LN.CNT 1599

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound comprised of a hydrophilic polymer  
covalently yet reversibly linked to a amine-containing ligand  
through a dithiobenzyl linkage is described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 10 USPATFULL on STN  
AN 2004:209023 USPATFULL  
TI Method for treating multi-drug resistant tumors  
IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES

Gabizon, Alberto, Jerusalem, ISRAEL  
PA ALZA Corporation (U.S. corporation)  
PI US 2004161455 A1 20040819  
AI US 2003-714085 A1 20031114 (10)  
RLI Continuation-in-part of Ser. No. US 2002-57839, filed on 25 Jan 2002,  
PENDING Continuation of Ser. No. US 2000-556610, filed on 21 Apr 2000,  
GRANTED, Pat. No. US 6365179  
PRAI US 2003-467070P 20030430 (60)  
US 1999-130897P 19990423 (60)  
DT Utility  
FS APPLICATION  
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 24 Drawing Page(s)  
LN.CNT 1449

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for administering mitomycin C to a multi-drug resistant cell and  
for reducing the toxicity of the compound are described. In the methods,  
mitomycin C is provided in the form of a prodrug conjugate, where the  
drug is linked to a hydrophobic moiety, such as a lipid, through a  
cleavable dithiobenzyl linkage. The dithiobenzyl  
linkage is susceptible to cleavage by mild thiolysis, resulting in  
release of mitomycin C in its original form. The linkage is stable under  
nonreducing conditions. The prodrug conjugate can be incorporated into  
liposomes for administration in vivo and release of mitomycin C in  
response to endogenous in vivo reducing conditions or in response to  
administration of an exogenous reducing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 10 USPATFULL on STN  
AN 2003:299858 USPATFULL  
TI Releasable linkage and compositions containing same  
IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES  
PA Alza Corporation (U.S. corporation)  
PI US 2003211079 A1 20031113  
US 6849270 B2 20050201  
AI US 2003-371169 A1 20030221 (10)  
RLI Continuation of Ser. No. US 2001-982336, filed on 15 Oct 2001, GRANTED,  
Pat. No. US 6605299 Continuation of Ser. No. US 2000-556056, filed on 21  
Apr 2000, GRANTED, Pat. No. US 6342244  
PRAI US 1999-130897P 19990423 (60)  
DT Utility  
FS APPLICATION  
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026  
CLMN Number of Claims: 47  
ECL Exemplary Claim: 1  
DRWN 16 Drawing Page(s)  
LN.CNT 1631

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound comprised of a hydrophilic polymer  
covalently yet reversibly linked to a amine-containing ligand  
through a dithiobenzyl linkage is described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 10 USPATFULL on STN  
AN 2003:78108 USPATFULL  
TI Conjugate having a cleavable linkage for use in a liposome  
IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES  
Gabizon, Alberto A., Jerusalem, ISRAEL  
PA Alza Corporation (U.S. corporation)  
PI US 2003054028 A1 20030320

US 6984396 B2 20060110  
AI US 2002-57839 A1 20020125 (10)  
RLI Continuation of Ser. No. US 2000-556610, filed on 21 Apr 2000, GRANTED,  
Pat. No. US 6365179  
PRAI US 1999-130897P 19990423 (60)  
DT Utility  
FS APPLICATION  
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026  
CLMN Number of Claims: 42  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 1366

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 10 USPATFULL on STN  
AN 2002:235998 USPATFULL  
TI Releasable linkage and compositions containing same  
IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES  
PA Alza Corporation (U.S. corporation)  
PI US 2002128195 A1 20020912  
US 6605299 B2 20030812  
AI US 2001-982336 A1 20011015 (9)  
RLI Continuation of Ser. No. US 2000-556056, filed on 21 Apr 2000, GRANTED,  
Pat. No. US 6342244  
PRAI US 1999-130897P 19990423 (60)  
DT Utility  
FS APPLICATION  
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026  
CLMN Number of Claims: 47  
ECL Exemplary Claim: 1  
DRWN 16 Drawing Page(s)  
LN.CNT 1619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 10 USPATFULL on STN  
AN 2002:69623 USPATFULL  
TI Conjugate having a cleavable linkage for use in a liposome  
IN Zalipsky, Samuel, Redwood City, CA, United States  
Gabizon, Alberto A., Jerusalem, ISRAEL  
PA ALZA Corporation, Mountain View, CA, United States (U.S. corporation)  
PI US 6365179 B1 20020402  
AI US 2000-556610 20000421 (9)  
PRAI US 1999-130897P 19990423 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Riley, Jezia  
LREP Simboli, Paul B., Mohr, Judy M.  
CLMN Number of Claims: 42

ECL Exemplary Claim: 1  
DRWN 25 Drawing Figure(s); 18 Drawing Page(s)  
LN.CNT 1360

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:05:45 ON 10 SEP 2006)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 18:07:25 ON  
10 SEP 2006

L1	188 S DITHIOBENZYL
L2	0 S L1 AND HYDROPHOLIC (3A) POLYMER?
L3	30 S L1 AND HYDROPHILIC (3A) POLYMER?
L4	28 S L3 AND AMINE
L5	22 DUP REM L4 (6 DUPLICATES REMOVED)
L6	10 S L5 AND POLYPEPTIDE

=> d his

(FILE 'HOME' ENTERED AT 18:05:45 ON 10 SEP 2006)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 18:07:25 ON  
10 SEP 2006

L1 188 S DITHIOBENZYL  
L2 0 S L1 AND HYDROPHOLIC (3A) POLYMER?  
L3 30 S L1 AND HYDROPHILIC (3A) POLYMER?  
L4 28 S L3 AND AMINE  
L5 22 DUP REM L4 (6 DUPLICATES REMOVED)  
L6 10 S L5 AND POLYPEPTIDE

=> s l3 and hydroxy?

L7 24 L3 AND HYDROXY?

=> s l7 not l6

L8 14 L7 NOT L6

=> dup rem l8

PROCESSING COMPLETED FOR L8

L9 10 DUP REM L8 (4 DUPLICATES REMOVED)

=> d l9 bib abs 1-10

L9 ANSWER 1 OF 10 USPATFULL on STN  
AN 2006:130804 USPATFULL  
TI Lyophilized liposome formulations and method  
IN Wong, Harry, Palo Alto, CA, UNITED STATES  
Zhang, Yuanpeng, Cupertino, CA, UNITED STATES  
Huang, Anthony Hei-Leung, Saratoga, CA, UNITED STATES  
PI US 2006110441 A1 20060525  
AI US 2005-261983 A1 20051028 (11)  
PRAI US 2004-623393P 20041028 (60)  
DT Utility  
FS APPLICATION  
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1046  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Formulations and methods for preparing a lyophilized composition  
comprising liposomes comprised of an unsaturated lipid and a hydrophobic  
drug associated with the liposome, and a cryoprotectant in a solution at  
a selected concentration. The phase transition temperature of the lipid  
is greater than the freezing point of the solution at the selected  
concentration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1  
AN 2005:490279 CAPLUS  
DN 143:39153  
TI Gene delivery mediated by liposome-DNA complex with cleavable PEG surface  
modification  
IN Huang, Shi-Kun; Zalipsky, Samuel  
PA Alza Corporation, USA  
SO PCT Int. Appl., 61 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051351	A2	20050609	WO 2004-US41170	20041119
	WO 2005051351	A3	20050714		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2546616	AA	20050609	CA 2004-2546616	20041119
	EP 1691780	A2	20060823	EP 2004-813485	20041119
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
PRAI	US 2003-524172P	P	20031121		
	WO 2004-US41170	W	20041119		
OS	MARPAT 143:39153				

AB A liposome composition and method for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a cationic lipid and (ii) a lipid joined to a hydrophilic polymer by a releasable linkage. The liposomes are associated with a nucleic acid for delivery to a cell. Thus, conjugates of methoxy-terminated polyethylene glycol with distearoylphosphatidylethanolamine are prepared without any cleavable linker (mPEG-DSPE), with a dithiobenzyl linker (PEG-H-DTB-DSPE), or with a sterically hindered DTB linker (PEG-Me-DTB-DSPE). Luciferase transfection efficiency with liposomes in BHK cell culture is decreased with the inclusion of mPEG-DSPE in the complexes, but at least partially restored when cleavable PEG-lipids are used. PEG-H-DTB-DSPE allowed transfection efficiencies 2.5-8-fold higher than the corresponding non-cleavable PEG formulation and nearly 1.5-fold greater than the corresponding PEG-Me-DTB-DSPE formation.

L9 ANSWER 3 OF 10 USPATFULL on STN  
AN 2005:220609 USPATFULL  
TI Liposome composition for delivery of therapeutic agents  
IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES  
Zhang, Weiming, San Francisco, CA, UNITED STATES  
Huang, Kew Shi Kun, Castro Valley, CA, UNITED STATES  
PI US 2005191344 A1 20050901  
AI US 2005-36523 A1 20050113 (11)  
PRAI US 2004-513864P 20040115 (60)  
DT Utility  
FS APPLICATION  
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 1673  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A neutral cationic lipid and liposomes prepared from the neutral cationic lipid are described. Liposomes comprised of the lipid are suitable for delivery of a polyanionic compound, such as a nucleic acid. The delivery can be performed in vivo or ex vivo. The neutral cationic lipid, which is neutral in charge at physiologic pH and positively charged at pH values less than physiologic pH, contains a polar head group that imparts solubility of the lipid and permits its packing into a liposomal lipid bilayer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 10 USPATFULL on STN  
AN 2005:202265 USPATFULL  
TI Preparation of lipid particles  
IN Zhang, Yuanpeng, Cupertino, CA, UNITED STATES  
PI US 2005175683 A1 20050811  
AI US 2004-970861 A1 20041022 (10)  
PRAI US 2003-514451P 20031024 (60)  
DT Utility  
FS APPLICATION  
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 1584

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for preparing lipid particles comprising producing discrete droplets of vesicle-forming lipids in a solvent, where the droplets have a diameter and a volume, introducing the discrete droplets into an aqueous solution to form lipid particles suitable for in vivo administration. The droplet may further contain any one or more of oils, surfactants, targeting ligands, markers, or therapeutic and diagnostic agents. The droplets may be generated by a system selected from a nebulizer, an atomizer, a venturi mist generator, a focused acoustic ejector, and an electrospray device. This method can be used to select or regulate the size and/or size distribution of the lipid particles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 10 USPATFULL on STN  
AN 2005:196366 USPATFULL  
TI Gene delivery mediated by liposome-DNA complex with cleavable PEG surface modification  
IN Huang, Shi-Kun, Castro Valley, CA, UNITED STATES  
Zalipsky, Samuel, Redwood City, CA, UNITED STATES  
PI US 2005170508 A1 20050804  
AI US 2004-993798 A1 20041119 (10)  
RLI Continuation-in-part of Ser. No. US 2003-371169, filed on 21 Feb 2003, GRANTED, Pat. No. US 6849270 Continuation of Ser. No. US 2001-982336, filed on 15 Oct 2001, GRANTED, Pat. No. US 6605299 Continuation of Ser. No. US 2000-556056, filed on 21 Apr 2000, GRANTED, Pat. No. US 6342244 Continuation-in-part of Ser. No. US 2000-685940, filed on 10 Oct 2000, PENDING  
PRAI US 2003-524172P 20031121 (60)  
US 1999-130897P 19990423 (60)  
US 1999-158693P 19991008 (60)  
DT Utility  
FS APPLICATION  
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 1619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A liposome composition and method for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a cationic lipid and (ii) a lipid joined to a hydrophilic polymer by a releasable linkage. The liposomes are associated with a nucleic acid for delivery to a cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2  
 AN 2004:905357 CAPLUS  
 DN 141:384303  
 TI Conjugates containing releasable linkage and pharmaceutical compositions  
 containing the same  
 IN Zalipsky, Samuel; Kiwan, Radwan  
 PA Alza Corporation, USA  
 SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 371,169.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004213759	A1	20041028	US 2003-723473	20031126
	US 6342244	B1	20020129	US 2000-556056	20000421
	EP 1579874	A2	20050928	EP 2005-8357	20000421
	EP 1579874	A3	20060125		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 2002128195	A1	20020912	US 2001-982336	20011015
	US 6605299	B2	20030812		
	US 2003211079	A1	20031113	US 2003-371169	20030221
	US 6849270	B2	20050201		
	AU 2004294350	A1	20050616	AU 2004-294350	20041124
	CA 2547255	AA	20050616	CA 2004-2547255	20041124
	WO 2005053749	A2	20050616	WO 2004-US41348	20041124
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005123597	A1	20050609	US 2005-35707	20050114
	US 2005271715	A1	20051208	US 2005-202913	20050812
PRAI	US 1999-130897P	P	19990423		
	US 2000-556056	A1	20000421		
	US 2001-982336	A1	20011015		
	US 2003-371169	A2	20030221		
	EP 2000-928321	A3	20000421		
	US 2000-556610	A1	20000421		
	US 2002-57831	A1	20020123		
	US 2003-723473	A	20031126		
	WO 2004-US41348	W	20041124		

AB A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in the form of their thiolytically cleavable macromol. conjugates. For example, the prodrug conjugate of mPEG dithiobenzyl nitrophenyl chloroformate with lysozyme was prepared and was found to release the active enzyme by cysteine.

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3  
 AN 2003:118404 CAPLUS  
 DN 138:158765

TI Liposome composition for delivery of nucleic acid  
 IN Huang, Shi-kun; Zalipsky, Samuel; Zhang, Wei-ming  
 PA Alza Corporation, USA  
 SO U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U. S. 6,342,244.  
 CODEN: USXXCO

DT Patent  
 LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003031704	A1	20030213	US 2001-20671	20011212
	US 6342244	B1	20020129	US 2000-556056	20000421
	EP 1579874	A2	20050928	EP 2005-8357	20000421
	EP 1579874	A3	20060125		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6974589	B1	20051213	US 2000-685940	20001010
	CA 2468627	AA	20030703	CA 2002-2468627	20021205
	WO 2003053409	A1	20030703	WO 2002-US41461	20021205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002359859	A1	20030709	AU 2002-359859	20021205
	EP 1465599	A1	20041013	EP 2002-794425	20021205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1617710	A	20050518	CN 2002-824903	20021205
	JP 2005514392	T2	20050519	JP 2003-554168	20021205
	US 2004166150	A1	20040826	US 2004-786747	20040225
	US 2005260261	A1	20051124	US 2005-133879	20050519
	US 2005271715	A1	20051208	US 2005-202913	20050812
PRAI	US 1999-130897P	P	19990423		
	US 1999-158693P	P	19991008		
	US 2000-556056	A2	20000421		
	US 2000-685940	A2	20001010		
	EP 2000-928321	A3	20000421		
	US 2000-556610	A1	20000421		
	US 2000-680614	A1	20001006		
	US 2001-294011P	P	20010529		
	US 2001-20671	A	20011212		
	US 2002-57831	A1	20020123		
	US 2002-161420	B1	20020528		
	WO 2002-US41461	W	20021205		

OS MARPAT 138:158765

AB A liposome composition for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a lipid that is neutral in charge at physiol. pH and pos. charged at pH values less than physiol. pH and (ii) a lipid joined to a hydrophilic polymer by a dithiobenzyl linkage. The liposomes are associated with a nucleic acid for delivery to a cell.

L9 ANSWER 8 OF 10 USPATFULL on STN

AN 2002:336918 USPATFULL

TI Liposome composition for improved intracellular delivery of a therapeutic agent

IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES  
 Allen, Theresa M., Edmonton, CANADA

Huang, Shi Kun, Castro Valley, CA, UNITED STATES  
 PI US 2002192275 A1 20021219  
 AI US 2002-108154 A1 20020326 (10)  
 PRAI US 2001-278869P 20010326 (60)  
 DT Utility  
 FS APPLICATION  
 LREP ALZA CORPORATION, P O BOX 7210, INTELLECTUAL PROPERTY DEPARTMENT,  
 MOUNTAIN VIEW, CA, 940397210  
 CLMN Number of Claims: 29  
 ECL Exemplary Claim: 1  
 DRWN 9 Drawing Page(s)  
 LN.CNT 1652  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A liposomal composition and a method of using the same for achieving  
 intracellular delivery of a liposome-entrapped agent is described. The  
 liposomes are composed of a pH sensitive lipid and include a targeting  
 ligand to direct the liposomes to a target cell. The liposomes also  
 include a stabilizing component, such a polymer-derivatized lipid, where  
 the polymer is attached to the lipid by a releasable linkage.  
 Administration of the liposomes results in cellular internalization and  
 destabilization of the liposome for intracellular delivery of the  
 entrapped agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 10 USPATFULL on STN  
 AN 2002:19081 USPATFULL  
 TI Releasable linkage and compositions containing same  
 IN Zalipsky, Samuel, Redwood City, CA, United States  
 PA Alza Corporation, Mountain View, CA, United States (U.S. corporation)  
 PI US 6342244 B1 20020129  
 AI US 2000-556056 20000421 (9)  
 PRAI US 1999-130897P 19990423 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Riley, Jezia  
 LREP Mohr, Judy M., Mahoney, Jacqueline F., Simboli, Paul B.  
 CLMN Number of Claims: 47  
 ECL Exemplary Claim: 1  
 DRWN 23 Drawing Figure(s); 16 Drawing Page(s)  
 LN.CNT 1629  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A compound comprised of a hydrophilic polymer  
 covalently yet reversibly linked to a amine-containing ligand through a  
 dithiobenzyl linkage is described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4  
 AN 2000:772486 CAPLUS  
 DN 133:340247  
 TI Releasable linkage and compositions containing same  
 IN Zalipsky, Samuel  
 PA Alza Corporation, USA  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000064483	A2	20001102	WO 2000-US10830	20000421
	WO 2000064483	A3	20010802		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,

CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2368793	AA	20001102	CA 2000-2368793	20000421
AU 2000043672	A5	20001110	AU 2000-43672	20000421
AU 770390	B2	20040219		
EP 1173221	A2	20020123	EP 2000-923572	20000421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002542386	T2	20021210	JP 2000-613473	20000421
NZ 514990	A	20040130	NZ 2000-514990	20000421
EP 1579874	A2	20050928	EP 2005-8357	20000421
EP 1579874	A3	20060125		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
NO 2001005169	A	20011219	NO 2001-5169	20011023
ZA 2001008724	A	20021023	ZA 2001-8724	20011023
ZA 2001008726	A	20030305	ZA 2001-8726	20011023
US 2005271715	A1	20051208	US 2005-202913	20050812
PRAI US 1999-130897P	P	19990423		
EP 2000-928321	A3	20000421		
US 2000-556610	A1	20000421		
WO 2000-US10830	W	20000421		
US 2002-57831	A1	20020123		

AB A compound comprised of a hydrophilic polymer covalently yet reversibly linked to an amine-containing ligand through a dithiobenzyl linkage is described. O- and p-methoxy polyethylene glycol-urethane-ethyldithiobenzyl-distearoylphosphatidyl ethanolamine were prepared and combined with dioleoyl phosphatidylethanolamine (DOPE) to obtain liposomes having an average diameter of 100 nm.

=>